CMAC 2004; 6(3) | CMAC

CMAC 2004; 6(3)

Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):214-217
PDF

The regimens of antimicrobial therapy of urinary tract infections in pregnant women based on data on antimicrobial susceptibility …
Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):218-223
PDF

The educational project “ERA” (Expert Recommendations on Antimicrobial Therapy) was established to join leading experts for the …
Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):224-231
PDF

This literature review presents approaches to the treatment of sarcoidosis, which are based on currently offered hypothesis of its …
Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):232-242
PDF

As a result of the increase in the number of diseases and conditions that are leading to secondary immunodeficiency, the problem of …
Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):243-251
PDF

To study the hypothesis of the mutant selection window (MSW) in a pharmacodynamic context, the susceptibility of a clinical isolate of …
Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):252-259
PDF

Translated and reprinted with permission from “Journal of Chemotherapy” 2003; 15:357-68

The pharmaceutical qualities of 34 ceftriaxone …
Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):260-272
PDF

Historically, intravenous immunoglobulins (ivIg) were initially used as replacement therapy in patients with antibody deficiency …
Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):273-281
PDF

Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):282-285
PDF

Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):286-289
PDF

Clinical Microbiology and Antimicrobial Chemotherapy.2004; 6(3):290-292
PDF